Scientific Publications:

Green RJ, Metlay JP, Propert KJ, Catalano PJ, Macdonald JS, Mayer RJ, Haller DG: Surveillance for second primary colorectal cancer after adjuvant chemotherapy: An analysis of INT-0089. Ann Int Med 136(4):261-269, 2002.

Macdonald JS: Vive la difference: Sex and fluorouracil toxicity. (Editorial) J Clin Oncol 20(6):1439-1441, 2002.

Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: The effect of undertreatment. Annals of Surgical Oncology 9(3):278-286, 2002.

Macdonald JS: Gastric Cancer. In: Vokes EE, Golomb HM (eds.) Oncologic Therapies, 2nd Edition. Springer-Verlag Berlin Heidelberg, pgs. 451-459, 2002.

Clements WM, Wang J, Sarnaik A, Kim OJ, Macdonald J, Groden JL, Fenoglio-Preiser C, Groden J, and Lowy AM: b-Catenin mutation is a frequent cause of Wnt pathway activation in Gastric Cancer. Cancer Res 62:3503-3506, 2002.

Presant GA, Jacobson J, Wolf W, Waluch V, Weitz I, Macdonald J: Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)?. A Southwest Oncology Group Study (SWOG 9006). Inv New Drugs (Submitted) 2002.

McCollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III, Fuchs CS: Outcomes and toxicity in African-American and Caucasian patients receiving adjuvant chemotherapy for colon cancer: A secondary analysis of INT-0089. Ann Int Med. (Accepted), February 2002.

Rothenberg ML, Benedetti JK, Maconald JS, Seay TE, Neubauer MA, George CS, Tanaka MS Jr, Giguere JK, Weiss GR, and Abbruzzese JL: Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: A Southwest Oncology Group Study (SWOG 9629). Annals of Oncology (Submitted). 2002.

Leichman CG, Benedetti JK, Macdonald JS, Doukas MA, Budd GT, Giguere JK, and Abbruzzese JL: Biochemical modulation of 5-fluorouracil through dihydropyrimidine dehydrogenase inhibition: A Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer (SWOG 9635). Inv New Drugs (accepted). 2002.

Gunderson LL, Sargent DJ, Tepper JE, O'Connell MJ, Allmer C, Smalley SR, Martenson JA, Haller DG, Mayer RJ, Rich TA, Ajani JA, Macdonald JS, and Goldberg RM: Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: A pooled analysis. Int J Radiat Oncol Biol Phys (Accepted) 2002.

Urba SG, Chansky K, Taylor SA, Paradelo JC, Macdonald JS, and Abbruzzese JL: Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma. A Southwest Oncology Group Study (SWOG 9801). In preparation, 2002.

Meyerhardt JA, Catalano PJ, Schrag D, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III, Fuchs CS: Association of hospital procedure volume and outcomes in high-risk curatively resected colon cancer. In press, 2002.

Joseph NE, Sigurdson ER, Hanlon AL, Wang H, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG: Accuracy of determining nodal negativity in colorectal cancer based on the number of nodes retrieved on resection. Annals of Surgical Oncology (accepted) 2002.

Macdonald JS, Astrow A: Adjuvant therapy of colon cancer. Sem Oncol 28(1):30-40, 2001.

Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB III, Cummings B, Gunderson L, Macdonald JS, Mayer RJ: Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 19(1): 157-163, 2001.

Macdonald JS, Goldberg R, Saltz LB, Haller DG, and Simon R: Critical analysis of recent phase III studies for the treatment of colorectal cancer: Implications for future clinical trial design. Oncology Spectrums 2(4): 255-269, 2001.

Macdonald JS: Gastrointestinal adenocarcinoma of unknown origin? Medscape Hematology-Oncology August 23, 2001.

Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup MJ, and Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. (INT-0116/SWOG-9008). N Engl J Med 345(10): 725-730, 2001.

Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, and Francini G: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345(15):1091-1097, 2001.

Macdonald JS: The case for CEA screening. In: Bleiberg H, Kemeny N, Rougier P, and Wilke H (eds), Colorectal Cancer: A clinical guide to therapy, Martin Dunitz, London, UK, pgs. 275-279, 2001.

Macdonald JS: Gastric cancer. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds), Clinical Oncology Updates Vol. 4, No. 3, Churchill Livingstone, New York, NY, pgs. 1-7, 2001.

Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB III, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ: Adjuvant therapy in rectal cancer : Analysis of Stage, Gender and Local Control- Final Report of INT 0114. (In preparation). 2001.

Shepherd T, Tolbert D, Benedetti J, Macdonald J, Stemmerman G, Wiest J, DeVoe G, Miller MA, Wang J, Noffsinger A, Fenoglio-Preiser C: Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology 118(6):1039-1044, 2000.

Grogan T, Fenoglio-Preiser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, Stemmerman G, Macdonald J, Richter L, Gallegos A, Powis G: Thioredoxin, a putative oncogene product is overexpressed in gastric carcinoma and associated with increased proliferation and increased survival. Human Pathol 31:475-481, 2000.

Macdonald JS, Jacobson JL, Ketchel SJ, Weiss G, Taylor S, Mills G, Kuebler JP, Rivkin SE, Conrad M: A phase II trial of topotecan in esophageal carcinoma: A Southwest Oncology Group Study (SWOG 9339). Inv New Drugs 18:199-202, 2000.

Macdonald JS: Any benefit from postoperative chemoradiotherapy in gastric cancer patients? Medscape Hematology-Oncology August 1, 2000.

Macdonald JS: How do downstage an inoperable rectosigmoid adenocarcinoma? Medscape Hematology-Oncology August 9, 2000.

Macdonald JS: How many options for first-line treatment of metastatic colorectal cancer? Medscape Hematology-Oncology October 10, 2000.

Macdonald JS: Lower limb edema and rash following 5-FU/Gemcitabine therapy? Medscape Hematology-Oncology October 10, 2000.

Macdonald JS, Jacobson JL, Modiano M, Moore Jr DF, Gandara DR, Schroder LE, and Chapman RA: A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: A Southwest Oncology Group Study (SWOG 9413). Inv New Drugs 18:269-273, 2000.

Macdonald JS: Treatment of unresectable colon cancer? Medscape Hematology-Oncology December 7, 2000.

Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler J, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy significantly improves the cure rate of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized Intergroup trial (RTOG 85-01). JAMA, 1999 (in press).

Tolbert D, Fenoglio-Preiser C, Noffsinger A, De Voe G, Macdonald J, Benedetti, J, Stemmermann GN: The relation of p53 gene mutations to gastric cancer subsite and phenotype. A Southwest Oncology Group Study (SWOG 9008). Cancer Causes and Control 10:227-231, 1999.

Tolbert DM, Noffsinger AE, Miller MA, DeVoe GW, Stemmermann GN, Macdonald JS and Fenoglio-Preiser CM: p53 immunoreactivity and single strand conformational polymorphism analysis often fail to predict p53 mutational status. Mod Pathol 12(1):54-60, 1999.

Macdonald JS: Gastric Cancer. In: Vokes EE, Golomb HM (eds.) Oncologic Therapies. Springer-Verlag Berlin Heidelberg, pgs. 703-718, 1999.

Rothenberg ML, Cox, JV, De Vore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE Jr., Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL and Von Hoff DD: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85(4):786-795, 1999.

Macdonald JS: From the bench to the bedside: Clinical management of unusual tumors. Curr Opin Oncol 11:25-26, 1999.

Macdonald JS: Adjuvant therapy for colon cancer. CA-Cancer J Clin 49(4):202-219, 1999.

Macdonald JS: Toxicity of 5-fluorouracil. Oncology 13(7) (Suppl. 3):33-34, 1999.

Leichman CG, Jacobson JR, Modiano MR, Daniels JR, Zalupski MM, Doroshow JH, Fletcher WS, Macdonald JS: Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group Pilot Trial (SWOG 9051). Cancer 86(5):775-781, 1999.

Macdonald JS: Carcinoembryonic antigen screening: pros and cons. Sem Oncol 26(5):556-560, 1999.

Holcombe RF, Jacobson J, Dakhil SR, Stewart RM, Betzing KS, Kannan K, Macdonald JS: Association of immune parameters with clinical outcome in stage III colon cancer: Results of Southwest Oncology Group Protocol 9009. Cancer Immunol Immunother 48:533-539, 1999.

Piedbois P, Rougier P, Buyse M, Pignon JP, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Leichman C, Macdonald J, Benedetti J, Lokich J, Fryer J, Brufman G, Isacson R, Laplanche A, Levy E: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16(1):301-308, 1998.

Macdonald JS: Gastric cancer. Oncologia Clinica 3(1):10-13, 1998.

Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser CM, Lovato LC, Bunn PA, Jr, Stemmerman G, Wells DJ, Macdonald JS and Meyskens FL, Jr: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer. A Southwest Oncology Group Study (SWOG 9000). Cancer Res 58:1149-1158, 1998.

Estes NC, Macdonald JS, Touijer K, Benedetti J and Jacobson J: Inadequate documentation and resection for gastric cancer in the United States: A preliminary report. American Surgeon 64:680-85, 1998.

Goldberg RM, Fleming TR, Tangen CM, Moertel CG, Macdonald JS, Haller DG and Laurie JA: Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection. Ann Int Med 129:27-35, 1998.

Macdonald JS: Cancer chemotherapy and the liver. Clinics in Liver Disease 2(3): 1998.

Meyskens FL Jr, Jacobson J, Nguyen B, Weiss GR, Gandara DR and Macdonald JS: Phase II trial of oral ?-all-trans-retinoic acid in hepatocellular carcinoma. A Southwest Oncology Group Study (SWOG 9157). Invest New Drugs 16:171-173, 1998.

Levy E, Piedbois P, Buyse M, Pignon J-P, Rougier P, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Leichman C, Macdonald J, Benedetti J, Lokich J, Fryer J, Brufman G, Isacson R, Laplanche A, Quinaux E, and Thirion P: Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 16(11):3537-3541, 1998.

Macdonald JS (Editor): Endocrine tumors. Curr Opin Oncol 10(1):37-65, 1998.

Ardalan B, Jacobson J, Restrepo A, Shinwari J, Goodwin JW, Balcerzak SP, Leichman CG, Samlowski W and Macdonald JS: A phase II study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA in patients with pancreatic adenocarcinoma. A Southwest Oncology Group Study (SWOG 9100). J Clin Oncol (Submitted), 1997.

Tepper JE, O'Connell MJ, Petroni G, Hollis D, Cooke E, Benson A, Cummings B, Gunderson LL, Macdonald JS, Martenson JA: Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of Intergroup 0114. J Clin Oncol 15(5):2030-2039, 1997.

Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR and Macdonald JS: Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: A Southwest Oncology Group Study. J Clin Oncol 15(6):2414-2419, 1997.

Munn RK, Henslee-Downey PJ, Romond EH, Marciniak EJ, Fleming DR, Messino MJ, Macdonald JS, Rayens MK, Harder EJ, Phillips GL, Thimpson JS: Treatment of leukemia with partially matched related bone marrow transplantation. Bone Marrow Transplant 19(5):421-427, 1997.

O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS: A controlled trial of 5-fluorouracil and low-dose leucovorin given for six months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15(1): 246-250, 1997.

Macdonald, J: Adjusting endpoints in pancreatic cancer: Are we moving the target? Oncology Times, Vol. XIX (1): 45, 1997.

Macdonald JS and Haller D: Update on adjuvant therapy of colon cancer. Tumori Suppl. to Vol. 83(1):S39-S41, 1997.

Macdonald JS: Therapies for advanced colorectal cancer: The role of interferon and leucovorin. Tumori Suppl. to Vol. 83(1):S67-S69, 1997.

Macdonald JS: Update on endocrine neoplasia: practical translation research. Curr Opin Oncol 9:43-44, 1997.

Macdonald JS: Adjuvant therapy for colon cancer. CA-Cancer J Clin 47(4):243-256, 1997.

Macdonald JS: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer (ASCO). Abstracts of Clinical Care Guidelines 9(6):16-18, 1997.

Benedetti JK, Burris HA III, Balcerzak SP, Macdonald JS: Phase II trial of topotecan in advanced gastric cancer: A Southwest Oncology Group study (SWOG 9150). Invest New Drugs 15:261-264, 1997

Wall JG, Benedetti JK, O'Rourke MA, Natale RB, Macdonald JS: Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group Study (SWOG 9151). Invest New Drugs 15:257-260, 1997.

Macdonald JS: The management of gastroesophageal carcinoma. Cancer Case presentations: The Tumor Board 1(6):1-14, 1997.

Macdonald JS, Benedetti JK, Modiano M and Alberts DS: Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group Trial (SWOG 9241). Invest New Drugs 15:357-359, 1997.

Poplin EA, Jacobson J, Herskovic A, Panella TJ, Valdivieso M, Hutchins LF, Macdonald JS: Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060. Cancer 78(9):1851-1856, 1996.

Fleming DR, Henslee-Downey PJ, Harder EJ, Romond EH, Marciniak E, Munn RK, Messino MJ, Macdonald JS, Bishop M, Rayens MK, Thompson JS, Foon KA: Allogeneic bone marrow transplantation with partially matched related donors for advanced acute lymphoblastic leukemia in children and adults. Bone Marrow Transplant 17(6):917-922, 1996.

Fleming T, Brown TD, Ross W, Macdonald JS: Phase II trial of trimetrexate in advanced esophageal cancer: A Southwest Oncology Group Study. Invest New Drugs 13(4):363-365.1996.

Macdonald JS: Endocrine tumors: Editorial overview. Curr Opin Oncol 8:29, 1996.

Macdonald, JS: Pancreatic Cancer: Editorial overview. Sem Oncol 23(2): 199, 1996.

Henslee-Downey PJ, Parrish RS, Romond EH, Marciniack E, Macdonald JS, Coffey C, Ciocci G, Thompson JS: Combined in vitro and in vivo T-lymphocyte depletion for the control of graft-versus-host disease following haplo-identical marrow transplant. Transplantation 61(5):738-745,1996.

Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, Reed JC: Immunohistochemical analysis of bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 149(5):1449-1457, 1996.

Macdonald JS: Cancer Consultation: "What further treatment for this colon cancer patient?", Primary Care and Cancer 16(7):35, 1996.

Greco, FA (Editor) and Evans WK, Holmes FA, Longo DL, Macdonald JS, Thigpen (consulting editors): Handbook of Commonly Used Chemotherapy Regimens, Precept Press, Chicago, IL, 1996.

Schnall SF and Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Seminars in Oncology 23(2):220-228, 1996.

Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88(20):1456-1466, 1996.

Martino RL, Fleming TR, Morrell LM, Ardalan B, Richman SP and Macdonald JS: Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-Fluorouracil in advanced gastric adenocarcinoma. Invest New Drugs 14(4):419-421, 1996.

Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, Eyre HJ, Solanki D, Gruz AB, Gagliano R, Estes NC, Tangen CM, Rivkin S: Adjuvant chemotherapy with 5-FU, adriamycin and mitomycin-C (FAM) vs surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group Study. Ann Surg Oncol 2(6):488-494, 1995.

Goldberg SL, Mangan KF, Klumpp TR, Macdonald JS, Thomas C, Mullaney MT and Au FC: Complications of peripheral blood stem cell (PBSC) harvesting: A review of 554 PBSC leukapheresis. J Hematother 4:85-90, 1995.

Berenberg JL, Tangen C, Macdonald JS, Hutchins LF, Natale RB, Oishi N, Guy JT, Fleming T: Phase II study of 5-fluorouracil and folinic acid in advanced gastric cancer: A Southwest Oncology Group Study. Cancer 76(5):715-719, 1995.

Macdonald JS: Lymphoma: "The Good Tumor". New Perspectives in Cancer Diagnosis and Management 3(3):67-68, 1995.

Fabian C, Giri S, Estes N, Tangen CM, Poplin E, Vogel S, Goodwin W, Rivkin S, Fleming TR, Macdonald JS: Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: A Southwest Oncology Group Pilot Study. Int J Radiat Oncol, Biol, Phys 32(2):457-464, 1995.

Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol, 13(12):2936-2943, 1995.

Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangan CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Maillaird: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med, 122(5):321-326, 1995.

Macdonald JS: Endocrine tumors: Editorial overview. Curr Opin Oncol 7:45-46, 1995.

Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, Macdonald JS: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study. J Clin Oncol 13(6):1303-1311, 1995.

Brown TD, Fleming TR, Goodman PJ, Macdonald JS, Pugh RP, O'Rourke T: A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: A Southwest Oncology Group Study. Anti-Cancer Drugs 6:219-223, 1995.

Macdonald JS, Schnall SF: Adjuvant treatment of gastric cancer. World J Surg 19:221-225, 1995.

Macdonald JS, Haller D, Weigel RJ: Endocrine System. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds), Clinical Oncology, Churchill Livingstone, New York, NY, pgs. 1047-1081, 1995.

Wolmark N, Macdonald JS: Biopsy as a prelude to definitive operative therapy for breast cancer. In: Macdonald JS, Haller DG, Mayer RJ (eds), Manual of Oncologic Therapeutics, Third Edition, J.B. Lippincott, Philadelphia, PA, pgs. 5-7, 1995.

Schnall SF, Macdonald JS: Gastrointestinal cancers. In: Macdonald JS, Haller DG, Mayer RJ (eds), Manual of Oncologic Therapeutics, Third Edition, J.B. Lippincott, Philadelphia, PA, pgs. 170-184, 1995.

Wittes RE, Macdonald JS: Endocrine System. In: Macdonald JS, Haller DG, Mayer RJ (eds), Manual of Oncologic Therapeutics, Third Edition, J.B. Lippincott, Philadelphia, PA, pgs. 237-245, 1995.

Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS: Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective randomized trial. J Clin Oncol 12(6):1323-1327, 1995.

Williamson SK, Tangen CM, Maddox AM, Spiridonidis H, Macdonald JS: Phase II evaluation of low dose continuous 5-fluorouracil (5FU) and weekly cis-platinum (CDDP) in advanced adenocarcinoma of the stomach. Am J Clin Oncol (CCT) 18(6):484-487, 1995.

Goldberg SL, Mangan KF, Klumpp TR, Cropper TM, Schnall SF, Macdonald JS: Lack of a graft-versus-leukemia effect in an immunologically privileged sanctuary site. Bone Marrow Transplant 14(2):180-181, 1994.

Hantel A, Tangen C, Balcerzak SP, Macdonald JS: Phase II trial of piroxantrone in gastric carcinoma. Invest New Drugs 12:159-161, 1994.

Hantel A, Tangen, Macdonald JS, Richman SP, Pugh RP, Laufman LR: Phase II trial of trimetrexate in untreated advanced gastric carcinoma. Invest New Drugs 12:155-157, 1994.

Macdonald JS (Commentary): Endocrine tumors: Molecular biology at the bedside? Curr Opin Oncol 6:51-52, 1994.

Macdonald JS and Havlin KA: Stomach. In: Foley, Vose, Armitage (eds) Current Therapy in Cancer, W.B. Saunders Company, Philadelphia, PA, pgs. 51-56, 1994.

Brown TD and Macdonald JS: Gastric, biliary, and pancreatic cancer. Chemotherapy and Combined Therapy. In: Carbone, P (ed) Current Therapy in Hematology/Oncology, Mosby Yearbook, 1994.

Klumpp TR, Herman JH, Mangan KF, Schnell MK, Goldberg SL, Macdonald JS: Lack of transmission of neutrophil and platelet antibodies by intravenous immunoglobulin in bone marrow transplant patients. Transfusion 34(8): 677-679, 1994.

Marshall ME, Tangen CM, Berenberg JL, Balcerzak SP, Brown T, Macdonald JS: Treatment of advanced colorectal carcinoma with 5-Fluorouracil, Leucovorin and Roferon-A®: A Southwest Oncology Group Study. Cancer Biother 9(4):301-306, 1994.

Poplin E, Tangen C, Harvey W, Macdonald JS: Hepatoma/merbarone. Investigat New Drugs 12:337-340, 1994.

BukowskI RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, Rivkin SE, Fleming TR, Macdonald JS: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group Study. Cancer 73(5):1505-1508, 1994.

Mangan KF, Mullaney MT, Klumpp TR, Goldberg SL, Macdonald JS: A retrospective comparison of three different methods for mobilization of peripheral blood stem cells. Prog Clin Biol Res 389:441-448, 1994.

O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994.

Macdonald JS: New approaches to the radioimmunodiagnosis and treatment of ovarian cancer. New Perspectives in Cancer Diagnosis and Management 2(2):45-46, 1994.

Brown TD, Goodman PJ, Fleming T, Macdonald JS, Craig JB, Einstein AB: Phase II trial of amonafide in advanced colorectal cancer: A Southwest Oncology Group Study. Anti-Cancer Drugs, 4:49-50, 1993.

Leichman CG, Tangan C, Macdonald JS, Leimert T, Fleming TR: Phase II trial of amonafide in advanced pancreas cancer: A Southwest Oncology Group Study. Invest New Drugs 11:219-221, 1993.

Jenkins TR, Tangen C, Macdonald JS, Weiss G, Chapman R, Hantel A: A phase II trial of piroxantrone in adenocarcinoma of the pancreas: A Southwest Oncology Group Study. Invest New Drugs 11:329-331, 1993.

Klumpp TR, Mangan KF, Glenn LD, Macdonald JS: Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 11:337-339, 1993.

Klumpp TR, Herman JH, Mangan KF, Macdonald JS: Graft failure following neutrophil-specific alloantigen mismatched allogeneic bone marrow transplantation. Bone Marrow Transplant 11:243-245, 1993.

Bukowski RM, Fleming TR, Macdonald JS, Oishi N, Taylor SA, Baker LH: Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma: A Southwest Oncology Group Study. Cancer Vol. 71(2):322-325, 1993.

Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, Rivkin SE, Fleming TR, Macdonald JS: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid: Southwest Oncology Group Study. Cancer Vol. 73(5):1505-1508, 1993.

Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA: Hepatic toxicity associated with fluorouracil plus levamisole: Adjuvant therapy. J Clin Oncol, 11(12):2386-2390, 1993.

Mangan KF, Mullaney MT, Klumpp TR, Goldberg SL, Macdonald JS: Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor. A phase I-II study. Stem Cells 11:445-454, 1993.

Harvey WH, Fleming TR, Goodman PJ, Harvey JH, Rivkin S, Macdonald JS: Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma. A Southwest Oncology Group Study. Invest New Drugs, 11:45-46, 1993.

Poplin E, Fleming T, Macdonald JS, Eisenberg P, Fisher RI, Conrad ME: Amonafide treatment of refractory esophageal cancer. A Southwest Oncology Group Study. Invest New Drugs 11:47-51, 1993.

Berenberg JL, Tangen C, Macdonald JS, Barlogie B, Laufman: VM-26 in gastric cancer: A Southwest Oncology Group study. Invest New Drugs, 11:333-334, 1993.

Macdonald JS: Non-Hodgkin's lymphoma: Editorial. Hem/Onc Annals, 1(1):11, 1993.

Macdonald JS: Diagnosis and therapy in venous thromboembolism: Editorial. Hem/Onc Annals, 1(2):97, 1993.

Kraut EH, Fleming T, Macdonald JS, Spiridonidis CH, Bradof JE, Baker LH: Phase II trial of merbarone in pancreatic carcinoma. A Southwest Oncology Group Study. Am J Clin Oncol, 16(4):327-328, 1993.

Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270(8):943-947, 1993.

Macdonald JS: New directions in the diagnosis of colorectal cancer recurrence. New Perspectives in Cancer Diagnosis and Management 1(2):31-32, 1993.

Macdonald JS: Colorectal cancer. New Perspectives in Cancer Diagnosis and Management 1(2):59-61, 1993.

Macdonald JS: Solid Tumors in Children: Editorial. Hem/Onc Annals, 1(3):163, 1993.

Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS: Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 12:337-345, 1993.

John WJ, Neefe JR, Macdonald JS, Cantrell J, Smith M: 5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Cancer 2(11):3191-3195, 1993.

Macdonald JS: Peripheral Blood Stem Cell Transplantation. Hem/Onc Annals, 2(1):12-13, 1993.

Macdonald JS: Gastric cancer: Chemotherapy of advanced disease. Hematol Oncol 10:37-42, 1992.

Bukowski RM, Tangan C, Lee R, Macdonald JS, Einstein AB, Peterson R, Fleming TR: Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: A Southwest Oncology Group Study. J Clin Oncol 10(12): 1914-1918, 1992.

Barkin JS, Brennan MF, Halvorsen RA, Macdonald JS, Rich TA: What's new in stomach cancer? Patient Care, pgs. 22 - 59, April 1992.

Klumpp TR, Mangan KF, Macdonald JS, Mesgarzadeh M: Fracture of the ilium: an unusual complication of bone marrow harvesting. Bone Marrow Transplant 9:503-504, 1992.

Macdonald JS and Thomas PRM: Therapy for locally advanced gastric cancer. Adv Oncol 8(4):17-20, 1992.

Klumpp TR, Herman JH, Macdonald JS, Schnell MK, Mullaney M and Mangan KF: Autoimmune neutropenia following peripheral blood stem cell transplantation. Am J Hematol 41:215-217, 1992.

Coffey RJ, Gunderson LL and Macdonald JS: Neoplasms of the anus. In: Calabresi P and Schein PS (eds) Medical Oncology 2nd Edition, McGraw-Hill, Inc., 1993.

Macdonald JS and Havlin KA: Etoposide in gastric cancer. Sem Oncol 19(6)Suppl. 13:59-62, 1992.

Klumpp TR and Macdonald JS: Esophageal Cancer: Epidemiology and Pathology. In: Ahlgren JD and Macdonald JS (ed) Gastrointestinal Oncology. JB Lippincott, Philadelphia, 71-81, 1992.

Macdonald JS, Hill MC and Roberts IM: Gastric Cancer: Epidemiology, Pathology, Detection and Staging. In: Ahlgren JD Macdonald JS (eds) Gastrointestinal Oncology. JB Lippincott, Philadelphia, 151-158, 1992.

Havlin KA and Macdonald JS: Gastric Cancer: Chemotherapy of Advanced Disease. In: Ahlgren JD and Macdonald JS (eds) Gastrointestinal Oncology. JB Lippincott, Philadelphia, 171-180, 1992.

Macdonald JS and Axelrod RS: Adjuvant therapy of colon and rectal cancer. In: Ahlgren JD and Macdonald JS (eds) Gastrointestinal Oncology. JB Lippincott, Philadelphia, 383-396, 1992.

Macdonald JS: Diagnostic Assays for Colon Cancer. J Natl Cancer Inst 84(15):1206-1207, 1992.

Kraut EH, Fleming T, Segal M, Neidhart JA, Behrens BC, Macdonald JS: Phase II study of pibenzimol in pancreatic cancer. A Southwest Oncology Group Study. Invest New Drugs, 9:95-96, 1991.

Brown TD, Goodman P, Fleming T, Macdonald JS, Hersh EM, Braun TJ: A phase II trial of recombinant tumor necrosis factor (RTNF) in patients with adenocarcinoma of the pancreas: A Southwest Oncology Group Study. J Immunother, 10:376-378, 1991.

Brown TD, Goodman PJ, Fleming T, Macdonald JS, O'Rourke T, Taylor SA, Neefe JR, Gaynor E: Phase II trial of recombinant DNA gamma interferon in advanced colorectal cancer: A Southwest Oncology Group Study. J Immunother, 10(5):379-382, 1991.

Brown T, Goodman P, Fleming T, Baker L, Macdonald JS: Phase II trial of menogaril in adenocarcinoma of the pancreas. A Southwest Oncology Group Study. Invest New Drugs, 9:77-78, 1991.

Morrell LM, Ardalan B, Richman SP, Goodman P, Fleming TR, Macdonald JS: A Phase II multi-institutional trial of low dose PALA and high dose 5-FU as a short term infusion in the treatment of adenocarcinoma of the pancreas: A Southwest Oncology Group Study. Cancer, 67(2):363-366, 1991.

Whitehead RP, Fleming TR, Macdonald JS, Ahmann FR, Garewal HS, Kuebler JP: A Phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin: A Southwest Oncology Group Study. Invest New Drugs 9:345-347, 1991.

Brown TD, Goodman PJ, Fleming T, Macdonald JS, O'Rourke T, Taylor SA, Neefe JR, Gaynor E. Phase II trial of recombinant DNA gamma interferon in advanced colorectal cancer: A Southwest Oncology Group Study. J Immunother 10:379-382, 1991.

Brown TD, Goodman PJ, Fleming T, Taylor SA, Macdonald JS: Phase II Trial of Echinomycin in Advanced Colorectal Cancer: A Southwest Oncology Group Study. Invest New Drugs, 9:113-114, 1991.

Knight WA, Goodman P, Taylor SA, Macdonald JS, Coltman CA, Castanzi JJ, Baker LH: Phase II trial of intravenous melphalan for metastatic colorectal carcinoma. A Southwest Oncology Group Study. Invest New Drugs 8:S87-S89, 1990.

Oishi N, Fleming T, Laufman L, Ungerleider JS, Natale RB, Einstein AB, Von Hoff DD, Macdonald JS: VM?26 in colorectal carcinoma: A Southwest Oncology Group Study. Invest New Drugs, 8:93-95, 1990.

Mortimer JE, Chestnut J, Schulman S, Macdonald JS, Kopecky K, Goodman G: High dose cisplatin in disseminated melanoma ? A comparison of two schedules: A Southwest Oncology Group Study. Cancer Chemother and Pharmacol, 25(5): 373-376, 1990.

VonHoff DD, Goodman PJ, Presant CA, Ruxer RL, Macdonald JS, Costanzi JJ, Stephens RL, Vogel SJ: A Phase II Trial of Continuous Infusion Vinblastine in Patients with Gastric Carcinoma: A Southwest Oncology Group Study. Eur J Cancer & Clin Oncol, 26(3): 405-407, 1990.

Whitehead RP, Earhart RH, Fleming T, Goodman P, Macdonald JS, Pollock T, Ungerleider JS: A phase II study of menogaril (NSC-269148) in colorectal carcinoma. A Southwest Oncology Group. Invest New Drugs, 8:295-297, 1990.

Meyskens FL, Kopecky K, Samson M, Hersh E, Macdonald JS, Jaffe H, Crowley J, Coltman C: Recombinant human interferon ?: Adverse effects in high-risk stage I and II cutaneous malignant melanoma. J Natl Cancer Inst, 82(12):1071, 1990.

Oishi N, Fleming TR, Laufman L, Ungerleider JS, Natale RB, Einstein AB, VonHoff DD, Macdonald JS: VM-26 in colorectal carcinoma. A Southwest Oncology Group Study. Invest New Drugs, 8:93-95, 1990.

Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B: A randomized trial of surgery in the treatment of single metastasis to the brain. N Engl J Med, 322:494-500 (February 22nd), 1990.

Von Hoff DD, Fleming T, Macdonald JS, Goodman PJ, VanDamme J, O'Rourke T, Feun LG, Lipschitz DA. Phase II evaluation of recombinant gamma interferon (r-GIFN) in patients with advanced pancreatic carcinoma: A Southwest Oncology Group Study. J Biol Response Modifiers, 9:584-587, 1990.

Clark DB, Ram MD, Macdonald JS, Rees ED, Engelberg J, Noble RC. How physicians deal with their own impending death. South Med J, 83(4): 441-447, 1990.

Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med, 322(6): 352-358 (February 8), 1990.

Whitehead RP, Fleming T, Macdonald JS, Goodman PJ, Neefe J, Braun TJ, Swinnen LJ, Hersh EM: A Phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: A Southwest Oncology Group Study. J Biol Response Modifiers 9:588-591, 1990.

Knight WA, Goodman P, Taylor SA, Macdonald JS, Coltman CA, Constanzi JJ, Baker LH: Phase II trial of intravenous melphalan for metastatic colorectal carcinoma. A Southwest Oncology Group Study. Invest New Drugs 8:S87-S89, 1990.

Treat J, Falchuk SC, Woolley PV, Ahlgren JD, Neefe JR, Smith FP, Macdonald JS, Schein PS: Therapy of Advanced Gastric Carcinoma, Am J Clin Oncol (CCT) 12(2):162?168, 1989.

Macdonald JS: Adjuvant therapy of colorectal cancer: Where do we stand? Oncology, 3(6):87?92, 1989.

Macdonald JS: Gastric Cancer: Current Status of Adjuvant Therapy, review, Oncology 3(4):67?70, 1989.

Romond EH, Macdonald JS, Martin CA, Dick A, Furst RW, Kilner JF, Engelbert J, Bosomworth PP: Integrative clinicopathological conference: bone marrow transplantation. Hosp Prac, 24(7):169?184, 1989.

Hazrati AM, Akrawi S, Hickey AJ, Wedlund P, Macdonald JS, DeLuca PP: Tissue Distribution of Indium-111 Labeled Poly(Glycolic Acid) Matrices Following Jugular and Hepatic Portal Vein Administration. J Controlled Release, 9 205-214, 1989.

Macdonald JS: Commentary: Adjuvant Therapy for Rectal Cancer. Is 5-FU Effective Without MeCCNU? Oncology, 3:11, 1989.

Macdonald JS: "An Approach to the Management of Gastric Cancer", Current Therapy in Hematology?Oncology, Brain and Carbone, Third Edition, B.D. Decker, Toronto, pp. 181?185, 1988.

Macdonald JS: Manual of Oncologic Therapeutics: "Gastrointestinal Cancers", J.B. Lippincott Company, 1988

Metcalfe MS, Macdonald JS: "Uncommon Pancreatic Tumors", Textbook of Uncommon Cancer, John Wiley and Sons Limited, New York, pp. 471?490, 1988.

Gohmann J, Macdonald JS: Chemotherapy of gastric cancer. Cancer Investigation, 1988.

Romond EH, Macdonald JS: "Chemotherapy of Gastric Cancer", Contemporary Issues in Clinical Oncology, H.O. Douglass, Jr. (Editor), Churchill Livingstone, Inc. Medical Publishers 205?220, 1988.

Macdonald JS, Gohmann JJ: Chemotherapy of advanced gastric cancer: present status, future prospects. Sem Oncol, Vol XV, Suppl. 4, 3:42?49, 1988.

Raju PI, Maruyama Y, Macdonald JS, DeSimone P: Treatment of unresectable pancreatic carcinoma using irradiation with concurrent intravenous 5?FU infusion therapy. Cancer Invest, 6(3), 263?266, 1988.

Macdonald JS, Gunderson LL, Steele G: Gastric Cancer, Principles and Practice of Oncology, V.T. DeVita, S. Hellman, S.A. Rosenberg (editors), Third Edition, J. B. Lippincott Company, New York (in press), 1988.

Macdonald JS, Metcalfe MS: Carcinoid Tumors, Decision Making in Oncology, P.S. Schein (editor), B.C. Decker Inc., New York, 1988.

Macdonald JS, Doukas MA: Pancreatic Islet Cell Tumor, Decision Making in Oncology, P.S. Schein (editor), B.C. Decker Inc., New York, 1988.

Macdonald JS, Romond EH: Adrenal Carcinoma, Decision Making in Oncology, P.S. Schein (editor), B.C. Decker Inc., New York, 1988.

Macdonald JS: Thyroid Carcinoma, Decision Making in Oncology, P.S. Schein (editor), B.C. Decker Inc., New York , 1988.

Macdonald JS: Esophageal Carcinoma, New Directions in Cancer Treatment, I. Magrath (editor), Springer?Verlag, New York, 1988.

Macdonald JS: Hepatocellular Carcinoma, New Directions in Cancer Treatment, I. Magrath (editor), Springer?Verlag, New York, 1988.

Macdonald JS: Neuroendocrine Tumors, New Directions in Cancer Treatment, I. Magrath (editor), Springer?Verlag, New York, 1988.

Budd GT, Fleming TR, Bukowski RM, McCracken JD, Rivkin SE, O'Bryan RM, Balcerzak SP, Macdonald JS: 5?Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: A randomized comparison. A Southwest Oncology Study. J Clin Oncol 5(2):272?277, 1987.

Macdonald JS: New Approaches to Management of Colorectal Carcinoma. Hosp Pract 22(5):185?204, 1987.

Marshall ME, Mendelsohn L, Butler K, Cantrell J, Harvey J, Macdonald J: Treatment of non?small cell lung cancer with coumarin and cimetidine. Cancer Treat Rep 71(1):91, 1987.

Marshall ME, Mendolsohn L, Butler K, Riley L, Cantrell J, Wiseman C, Taylor R, Macdonald JS: Treatment of metastatic renal cell carcinoma with coumarin (1,2?Benzopyrone) and cimetadine: pilot study. J Clin Oncol 5(6):862?866, 1987.

Macdonald JS: Adjuvant therapy of gastrointestinal cancer. Adjuvant Therapy of Cancer V, Grune and Stratton, 479?496, 1987.

Garrison J, Marshall ME, Macdonald JS: Unusual Skin Reaction to Echinomycin (NSC #526417). Cancer Treat Rep 71(4):433?434, 1987.

Ash RC, Casper J, Serwint MS, Coffey C, Bruckman JE, Truitt R, Greenwood M, Geil J, Romond E, Camitta B, Macdonald JS, Thompson J, Maruyama Y: Extending the application of allogeneic marrow transplantation for leukemic patients who lack matched sibling donors, utilizing partially matched donors in concert with T?cell depletion for GVHD prophylaxis. Progress in Bone Marrow Transplantation, Vol. 53, June 1987.

Chapman R, Fleming TR, Van Damme J, Macdonald J: Cisplatin, vinblastine, and mitoguazone in squamous cell carcinoma of the esophagus. A Southwest Oncology Group Study. Cancer Treat Rep 71:1185?1187, 1987.

Henslee PJ, Thompson JS, Romond EH, Doukas MA, Metcalfe M, Marshall ME, Macdonald JS: T?cell depletion of HLA and haploidal marrow reduces graft?versus?host disease but it may impair a graft?versus?leukemia effect. Transplant Proc, Vol XIX, 1:2701?2706, 1987.

Raju PI, Maruyama Y, DeSimone P, Macdonald JS: Treatment of Liver Metastases with a Combination of Chemotherapy and Hyperfractionated External Radiation Therapy. Am J Clin Oncol 10(1) 41-43, 1987.

Budd GT, Fleming TR, Bukowski RM, McCracken JD, Rivkin SE, O'Bryan RM, Balcerzak SP, Macdonald JS: 5-Fluorouracil and Folinic Acid in the Treatment of Metastatic Colorectal Cancer: A Randomized Comparison. A Southwest Oncology Group Study. J Clin Oncol, 5(2) 272-277, 1987.

Raju PI, Maruyama Y, DeSimone P, Macdonald J: Treatment of liver metastases with a combination of chemotherapy and hyperfractionated external radiation therapy. Am J Clin Oncol, 10(1):41?43, 1987.

Macdonald JS, Cohn I, Gunderson L: Cancer of the stomach. Cancer: Principles & Practice of Oncology, DeVita, Hellman, Rosenberg, etc., Second Edition. 659?686, 1985.

Brennan M, Macdonald JS: Cancer of endocrine system. Cancer: Principles & Practice of Oncology. DeVita, et al. Second Edition, pp. 1179?1228, 1985.

Cady B, Gunderson L, Macdonald J: Cancer of the Hepatobiliary System. Cancer: Principles & Practice of Oncology. DeVita, et al. Second Edition, pp. 741?758, 1985.

Romond EH, Metcalfe M, Macdonald JS: Palliative chemo/hormonal therapy. Semin Oncol 4:384?389, 1985.

DeSimone PA, Martin CA, Macdonald JS, et. al: Recurrent breast cancer: An integrative CPC. Hosp Pract 21:158?180, 1985.

Gad?el?Mawla N, Macdonald JS, Khaled H: Hexamethymelamine in advanced head and neck cancer ? A Phase II study. Am J Clin Oncol 7:205?208, 1984.

Gad?el?Mawla N, Abul?ela M, Mansour MA, Macdonald JS: Preoperative chemotherapy in relatively advanced head and neck cancer. Am J Clin Oncol 7:3, 1984.

Macdonald JS: Disseminated Pancreatic Carcinoma: Disease Overview/Case Presentation. Bristol Labs, 1984.

Macdonald JS: Gastrointestinal Cancer: Update 1984. Bristol Labs, 1984.

Kisner DL, Macdonald JS: The impact of chemotherapy on the treatment of gastric cancer. In Muggia, F.M. (Ed.): Cancer Chemotherapy, Vol 1, in McGuire, W.A. (Ed.): Series in Oncology. Hingham, Massachusetts, Martinus Nijhoff Publishers, 1983, pp. 281?302.

Macdonald JS: Oncology perspective on prostate cancer. In Yancik, R. (Ed.): Perspectives on Prevention and Treatment of Cancer in the Elderly. New York, Raven Press, 1983, pp. 143?146.

Kisner DL, Macdonald JS: Mitomycin?C in the treatment of gastric and pancreatic carcinomas. In Rozencweig, M. (Ed.): Mitomycin?C. Amsterdam, Excerpta Medica, 1983, pp. 281?302.

Gisselbrecht C, Smith FP, Macdonald JS, Boiron M, Woolley PV, Schein PS: The effect of sequential addition of the nitrosourea, chlorozotocin, to the FAM combination in advanced gastric cancer. Cancer 51:1792?1794, 1983.

Macdonald JS: Gastric Carcinoma Flow Sheet, Bristol Labs, 1983.

Goldin A, Chirigos MA, Macdonald JS, Fefer A, Mihich E: Biological response modifiers and adjuvant chemotherapy: Consideration of selected preclinical investigations in relation to clinical potential. In Mathe, G. and Muggia, F.M. (Eds.): Recent Results in Cancer Research, Vol. 80. Berlin, Heidelberg, Springer?Verlag, 1982, pp. 351?356.

Macdonald JS, Haller D, Kisner D: Adjuvant chemotherapy in colon and gastric cancer. In Mathe, G. and Muggia, F.M. (Eds.): Recent Results in Cancer Research, Vol. 80. Berlin, Heidelberg, Springer?Verlag, 1982, pp. 284?290.

Kisner DL, Macdonald JS: Chemotherapy of metastatic gastrointestinal cancers: Prospects for future adjuvant systemic therapies. In Mathe, G. and Muggia, F.M. (Eds.): Recent Results in Cancer Research, Vol. 80. Berlin, Heidelberg, Springer?Verlag, 1982, pp. 291?295.

Schein PS, Winokur S, Macdonald JS, Woolley PV: Long term complications of cytotoxic and immunosuppressive chemotherapy. In Holland, J. and Frei,, E. III (Eds): Cancer Medicine, Second Edition, Philadelphia, Lea & Sebiger, 1982, pp. 759?774.

Macdonald JS, Marsoni S, Bruno S, Poster D: Current status of clinical trials of m?AMSA, dihydroxyanthracenedione, and deoxycoformycin. In Mathe, G. and Muggia, F.M. (Eds.): Recent Results in Cancer Research Vol. 80. Berlin, Heidelberg, Springer?Verlag, 1982, pp. 323?330.

Macdonald JS: Small Bowel Adenocarcinoma. Letter to the Editor. JAMA, 247:1049, 1982.

Macdonald JS, Gunderson L, Cohn I: Cancer of the pancreas. In DeVita, V., Hellman, S., and Rosenberg, S. (Eds.): Principles and Practice of Oncology. Philadelphia, J.B. Lippincott Company, 1982, pp. 563?589.

Macdonald JS, Gunderson L, Adson M: Cancer of the hepatobiliary system. In DeVita, V., Hellman, S., and Rosenberg, S. (Eds.): Principles and Practice of Oncology. Philadelphia, J.B. Lippincott Company, 1982, pp. 534?562.

Macdonald JS, Gunderson L, Adson M: Cancer of the hepatobiliary system. In DeVita, V., Hellman, S., and Rosenberg, S. (Eds.): Principles and Practice of Oncology. Philadelphia, J.B. Lippincott Company, 1982, pp. 590?615.

Sugarbaker P, Macdonald JS, Gunderson L: Colorectal cancer. In DeVita, V., Hellman, S., and Rosenberg, S. (Eds.): Principles and Practice of Oncology. Philadelphia, J.B. Lippincott Company, 1982, pp. 643?723.

Brennan M, Macdonald JS: Cancer of the endocrine system: The endocrine pancreas. In DeVita, V., Hellman, S., and Rosenberg, S. (Eds.): Principles and Practice of Oncology. Philadelphia, J.B. Lippincott Company, 1982, pp. 1001?1019.

Mihich E, Macdonald JS, Oettgen H, Waldmann T, Jasmin C, Serrou B, Grimm E, Rosenberg S, Blomgren H: Symposium on Cancer Immunotherapy at the 12th International Congress of Chemotherapy, Florence, Italy, July 14?24, 1981. In Periti, P. and Grassi, G. (Eds.): Current Chemotherapy and Immunotherapy, Vol. 2. American Society of Microbiology, Washington, D.C., 1982, pp. 1150?1154.

Hubbard SM, Macdonald JS: An introduction to current controversies in cancer management: Stage I testicular cancer, case in point. Cancer Treat Rep 66:1?3, 1982.

Sugarbaker P, Gunderson L, Macdonald J: Cancer of the anal region. In DeVita, V., Hellman, S., and Rosenberg, S. (Eds.): Principles and Practice of Oncology. Philadelphia, J.B. Lippincott Company, 1982, pp. 724?731.

Macdonald JS: Summary of session on diagnostic procedures, histopathology, and prevention for the UICC International Conference on Clinical Oncology, August 13?17, 1981, Geneva, Switzerland. UICC Bulletin, Spring, 1982.

Bruno S, Poster DS, Bono VH, Macdonald JS, Kubota T: "High dose" thymidine in clinical oncology. Cancer Treat Rep 65:57?63, 1981.

Maguire PJ, Macdonald JS: Hypocalcemia associated with a calcitonin?producing hepatocellular carcinoma. Arch Intern Med 141:687?688, 1981.

Ardalan B, Macdonald JS, Cooney D, Lippman M, Schein PS: The potential for clinical application of in vitro assays predicting 5?fluorouracil sensitivity in man. Cancer Treat Rep 65 (Suppl 3): 57?62, 1981.

Poster D, Penta JS, Bruno S, Bono VH, Macdonald JS: 2'Deoxycoformycin ? a new anticancer agent. Cancer Clin Trials 4:209?213, 1981.

Poster D, Bruno S, Macdonald JS: Indicine?N?Oxide: A new antitumor agent. Cancer Treat Rep 65:53?56, 1981.

Macdonald JS, Weiss RB, Poster D, Hammershaimb L: Subacute and chronic toxicities associated with nitrosourea therapy. In Prestayko, A.W., Crooke, S.T., Baker, L.H., Carter, S.K., and Schein, P.S. (Eds.): Nitrosoureas: Current Status and New Developments. New York, Academic Press, Inc., 1981, pp. 145?154.

Muggia FM, Carter SK, Macdonald JS: The Cancer Therapy Evaluation Program. Semin Oncol 8:394?402, 1981.

Killen JY, Macdonald JS: Investigational new drugs in the treatment of small cell bronchogenic carcinoma. In Greco, A., Oldham, R.K., and Bunn, P. (Eds.): Small Cell Lung Cancer, New York, Grune and Stratton, 1981, pp. 399?412.

Phillips TM, Macdonald JS, Lewis MG: Towards tumor antibody isolation and characterization in immune complexes. In Serrou, B. and Rosenfeld, C. (Eds.): Immune Complexes and Plasma Exchanges in Cancer Patients. Amsterdam, New York, Oxford, Elsevier/North Holland Biomedical Press, 1981, pp. 3?27.

Israel L, Edelstein R, Samak R, Baudelot J, Macdonald JS, Breau JL, Manonni P, Radot E: Clinical results of multiple plasmapheresis in patients with advanced cancer. In Serrou, B. and Rosenfeld, C. (Eds.): Immune Complexes and Plasma Exchanges in Cancer Patients. Amsterdam, New York, Oxford, Elsevier/North Holland Biomedical Press, 1981, pp. 309?327.

Goldin A, Venditti J, Macdonald JS, Muggia FM, Henney JE, DeVita VT: Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer 17:129?142, 1981.

Kisner D, Schein PS, Macdonald JS: Recent results of clinical therapeutic trials for gastrointestinal malignancy conducted in the United States. In Klein, H.O. (Ed.): Recent Results in Cancer Research, Vol. 79. Berlin, Springer?Verlag, 1981, pp. 28?40.

Ardalan B, Glazer RI, Kensler TW, Jayaram HN, Van Pham T, Macdonald JS, Cooney DA: Synergistic effect of 5?fluorouracil and N?(phosphonacetyl)?L?Aspartate with Ribonucleic Acid synthesis in a human mammary carcinoma. Biochem Pharmacol 30:2045?2049, 1981.

Poster D, Penta J, Bruno S, Macdonald JS: Delta?9? tetrahydro?cannabinol in clinical oncology. JAMA 245:2047?2051, 1981.

Cambareri RJ, Smith FP, Macdonald JS, Haidak DJ, Ueno WM, Hoth DH, Woolley PV, Schein PS: CAMP (cyclophosphamide, doxorubicin, methotrexate and procarbazine) for epidermoid and large cell anaplastic carcinoma of the lung. Cancer Treat Rep 65:317?320, 1981.

Smith FP, Schein PS, Macdonald JS, Woolley PV, Ornitz R, Rogers C: Fast neutron irradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 7:1527?1531, 1981.

Penta J, Poster D, Bruno S, Macdonald JS: Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. J Clin Pharmacol 21:11S?22S, 1981.

Poster D, Penta J, Bruno S, Macdonald JS: ICRF?187 in clinical oncology. Cancer Clin Trials 4:143?146, 1981.

Macdonald JS, Phillips TM, Smith FP, Lewis M, Israel L: The effect of aggressive plasma exchange on immune complex levels in plasma of patients with metastatic cancer. In Serrou, B. and Rosenfeld, C. (Eds.): Immune Complexes and Plasma Exchanges in Cancer Patients. Amsterdam, New York, Oxford, Elsevier/North Holland Biomedical Press, 1981, pp. 243?251.

Editor: Monfardini S, Brunner K, Crowther D, Olive D, Macdonald JS, Eckhardt S. Whitehouse J (Eds.): Manual of Cancer Chemotherapy, Third Edition, Imprimerie W. Gassman, Geneva, 1981, 230 pp.

Schein PS, Macdonald JS, Woolley PV, Smith FP, Hoth DF, Boiron M, Gisselbrecht C, Brunet R, Lagarde C: The FAM regimen for gastric cancer: A progress report. In Carter, S.K., Sakurai, Y., and Umezawa, H. (Eds.): Recent Results in Cancer Research, Vol. 76, Berlin, Heidelberg, Springer?Verlag, 1981, pp. 241?243.

Macdonald JS: Therapy of Gastrointestinal Cancer. Br J Cancer 43:707?708, 1981.

Ardalan B, Cooney DA, Jayaram HN, Carrico CK, Glazer RI, Macdonald JS, Schein PS: Mechanisms of sensitivity and resistance of murine tumors to 5?fluorouracil. Cancer Res 40:1431?1437, 1980.

Ardalan B, Macdonald JS, Cooney D, Lippman M, Schein PS: Prediction of clinical response to 5?fluorouracil containing chemotherapy: Preliminary results of in vitro assay in human breast cancer. In Mathe, G. and Muggia, F. (Eds): Recent Results in Cancer Research, Vol. 74. Berlin, Heidelberg, New York, 1980, Springer?Verlag, pp. 84?90.

Bayssas M, Ribaud P, Misset JL, Hayat M, Machover D, Schwarzenberg L, Jasmin C, Pico JL, Musset M, De Vassal F, Serrou B, Montero JL, Imbach JL, Macdonald JS, Mathe G: Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU and chlorozotocin. IV. Preliminary comparison of Phase II clinical trial results of the three compounds. Cancer Clin Trials (1980).

Gullo JJ, Citron M, Smith FP, Macdonald JS, Schein PS: Management of gastric and pancreatic cancer. In Aisner, J., and Chang, P. (Eds): Cancer Treatment Research. The Hague, Boston, London, Martinus Nijhoff Publishers, 1980, pp. 119?141.

Phillips TM, Macdonald JS, Smith FP, Queen WD, Lewis MG, Israel L: Aggressive plasmapheresis in patients with metastatic cancer: Its effect on circulating immune complexes. In Serrou, B. and Rosenfield, C. (Eds): New Trends in Human Immunology and Cancer Immunotherapy. Paris, Doin?Saunders, 1980, pp. 521?530.

Schein PS, Slavik M, Smythe T, Hoth D, Smith F, Macdonald JS, Woolley, P.: Phase I clinical studies with WR 2721. Cancer Clin Trials 3:217?221, 1980.

Macdonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith, F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C: 5?Fluorouracil, Doxorubicin, and Mitomycin (FAM): Combination chemotherapy for advanced gastric cancer. Ann Intern Med 93:533?536, 1980.

Schein PS, Slavik M, Smythe T, Hoth D, Smith F, Macdonald JS, Woolley, PV: Phase I clinical trial of apirogermanium. Cancer Treat Rep 64:1051?1056, 1980.

Ardalan B, Cooney D, Macdonald JS: Physiological and pharmacological determinants of sensitivity and resistance to 5?fluorouracil in lower animals and man. In Garattini, S., Goldin, A., Hawking, F., and Kopin, I. (Eds.): Advances in Pharmacology and Chemotherapy, Vol. 17. New York, Academic Press, 1980, pp. 289?320.

Smith FP, Macdonald JS, Schein PS, Ornitz RD: Cutaneous seeding of pancreatic cancer by skinny?needle aspiration biopsy. Arch Intern Med. 140:855, 1980.

Weiss RB, Charles LM, Macdonald JS: m?AMSA: An exciting new drug in the National Cancer Institute Drug Development Program. Cancer Clin Trials 3:203?209, 1980.

D, Penta J, Marsoni S, Bruno S, Macdonald JS: Bisdiketopiperazine derivatives in clinical oncology: ICRF?159. Cancer Clin Trials 3:315?320, 1980.

Macdonald JS, Schein PS: Endocrine tumors. In Bergevin, P.R., Blom, J., and Tormey, D.C. (Eds): Guide to Therapeutic Oncology. Baltimore and London, Williams & Wilkins, 1979, pp. 497?518.

Macdonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS: F?fluorouracil, adriamycin, and mitomycin?C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 44:42?47, 1979.

Butler TP, Macdonald JS, Smith FP, Smith LF, Woolley PV, Schein PS: 5?fluorouracil, adriamycin, and mitomycin?C (FAM) chemotherapy for adenocarcinoma of the lung. Cancer 43:1183?1188, 1979.

Macdonald JS, Woolley PV, Schein PS: Clinical Strategies in the chemotherapy of gastrointestinal cancer. In Carter, S.K. (Ed.): Recent Results in Cancer Research, Vol. 70. Berlin, Heidelberg, New York, Springer?Verlag, 1979. pp. 179?185.

Macdonald JS, Hoth DF, Schein PS: Preclinical and clinical studies on chlorozotocin, a new nitrosourea with decreased bone marrow toxicity. In Carter, S.K. (Ed): Recent Results in Cancer Research, Vol. 70. Berlin, Heidelberg, New York, Springer?Verlag, 1979, pp. 83?89.

Ardalan B, Macdonald JS, Cooney D, Schein PS: Studies on mechanism of 5?fluorouracil resistance in murine and human tumors. Bull Cancer 66:55?59, 1979.

Woolley PV, Macdonald JS, Smythe T, Haller DG, Hoth DF, Rosenoff S, Schein PS: Phase II trial of ftorafur, adriamycin and mitomycin?C (FAM II) in advanced gastric adenocarcinoma. Cancer 44:1211?1214, 1979.

Wiggans RG, Woolley PV, Smythe T, Hoth DF, Macdonald JS, Schein PS: Phase II trials of tamoxifen in advanced breast cancer. Cancer Chemother Pharmacol 3:45?48, 1979.

Woolley PV, Macdonald JS, Hoth DF, Smith FP, Schein PS: Current management of the gastrointestinal malignancies. In Thatcher, N. (Ed): Advances in Medical Oncology, Research, and Education, Vol. 9, Digestive Cancer. Oxford and New York, Pergamon Press, 1979, pp. 295?299.

Woolley PV, Macdonald JS, Schein PS: Chemotherapy in the management of gastric carcinoma. In Thatcher, N. (Ed): Advances in Medical Oncology, Research, and Education, Vol. 9, Digestive Cancer. Oxford and New York, Pergamon Press, 1979, pp. 269?272.

Macdonald JS, Neefe J: Chemotherapy in the management of gastrointestinal cancer. J Abdomin Surg 21:126?133, 1979.

Hayat M, Bourut C, Chenu E, Montero JL, Imbach JL, Macdonald JS, Mathe G: Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice. Cancer Chemother Pharmacol 3:217?221, 1979.

Lewis MG, Phillips TM, Rowden G, Macdonald JS: Immune derangement in patients with malignant melanoma. In Kumar, S. (Ed): Advances in Medical Oncology, Research, and Education, Vol. 10, Clinical Cancer Principal Sites 1. Oxford and New York, Pergamon Press, 1979, pp. 103?111.

Schein PS, Macdonald JS, Hoth DF, Woolley PV: The FAM (5?fluorouracil, adriamycin, mitomycin?C) and SMF (streptozotocin, mitomycin?C, 5?fluorouracil) chemotherapy regimens. In Carter, S.K. and Crooke, S.T. (Eds): Mitomycin, C: Current Status and New Developments. New York, San Francisco, London, Academic Press, 1979, pp. 133?143.

Schein PS, Smith F, Woolley PV, Hoth DF, Macdonald JS: Chemotherapy of pancreatic cancer. In Thatcher, N. (Ed): Advances in Medical Oncology, Research, and Education, Vol. 9, Digestive Cancer. Oxford and New York, Pergamon Press, 1979, pp. 187?190.

Wiggans RG, Woolley PV, Macdonald JS, Ueno W, Schein PS: Phase II trial of streptozotocin, mitomycin?C, and 5?fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 41:387?391, 1978.

Schein PS, Macdonald JS, Hoth D, Woolley PV: Anticancer antibiotics: Mitomycin?C: Experience in the United States, with emphasis on gastric cancer. Cancer Chemother Pharmacol 1:73?75, 1978.

Bayly T, Kisner D, Sybert A, Macdonald JS, Tsou E, Schein PS: Tetracycline and quinacrine in the control of malignant pleural effusion. A randomized trial. Cancer 41:1188?1192, 1978.

Haller DG, Woolley PV, Macdonald JS, Smith LF, Schein P: A Phase II trial of 5?fluorouracil, adriamycin, and mitomycin?C (FAM) in advanced colorectal cancer. Cancer Treat Rep 62:563?565, 1978.

Woolley PV, Macdonald JS, Schein PS: Treatment of advanced gastric cancer. Rev Lat Am Quimioterap 10:21?29, 1978.

Macdonald JS: GI Cancer: The Statistics. Med Times 106:83?110, 1978.

Wiggans RG, Jacobson RJ, Fialkow P, Woolley PV, Macdonald JS, Schein PS: Probable clonal origin of acute myeloblastic leukemia following radiation and chemotherapy of colon cancer. Blood 52:659?663, 1978.

Macdonald JS, Lippman ME, Woolley PV, Petrucci PP, Schein PS: Hepatic estrogen and progesterone receptors in an estrogen associated neoplasm. Cancer Chemother Pharmacol 1:135?138, 1978.

Smith FP, Slavik M, Macdonald JS: Association of breast cancer with meningioma. Cancer 42:1992?1994, 1978.

Hoth DF, Woolley PV, Green D, Macdonald JS, Schein PS: A Phase II trial of chlorozotocin. Clin Pharmacol Ther 23:712?722, 1978.

Israel L, Edelstein R, Macdonald JS, Weiss J, Schein PS: Immunological and plasma protein changes in cancer patients following a single plasmapheresis. Biomedicine 28:292?297, 1978.

Cohen MI, Widerlite LW, Schecter GT, Jaffe E, Fischman AB, Schein PS, Macdonald JS: Gastrointestinal involvement in the Sezary syndrome. Gastroenterology 73:145?149, 1977.

Isner J, Macdonald JS, Schein PS: Spontaneous streptococcus pneumonia peritonitis in a patient with metastatic gastric cancer: A case report and etiologic consideration. Cancer 39:2306?2309, 1977.

Macdonald JS, Widerlite L, Schein PS: Biology, diagnostic and chemotherapeutic management of pancreatic malignancies. Adv Chemother Pharmacol 14:107?142, 1977.

Woolley PV, Macdonald JS, Schein PS: Chemotherapy of malignancies of the gastrointestinal tract. In Jerzy Glass, G.B. (Ed.): Progress of Gastroenterology, Vol III, New York, Grune & Stratton, Inc., 1977, pp. 671?692.

Peterson R, Haidak D, Ferris R, Schein PS, Macdonald JS: Blastic bone metastasis in Zollinger?Ellison Syndrome. Radiology 118:63?64, 1976.

Schein PS, Macdonald JS, Edelson R: Cutaneous T?cell lymphoma. Cancer 38:1859?1861, 1976.

Macdonald JS, Widerlite L, Schein PS: Current diagnosis and management of pancreatic cancer. J Natl Cancer Inst 56:1093?1099, 1976.

Macdonald JS, Schein PS: Mechanism and management of malnutrition states in patients with malignancy. Clin Gastroenterol 5:809?826, 1976.

Macdonald JS: The immunobiology of colorectal cancer. Semin Oncol 3:421?431, 1976.

Wiggans G, Schein P, Macdonald JS, Schellinger D, Harbert J: Initial evaluation of computerized axial tomography for the diagnosis of pancreatic cancer. Lancet 2:233?235, 1976.

Wooley PV, Macdonald JS, Schein PS: Chemotherapy of colorectal carcinoma. Semin Oncol 3:415?420, 1976.

Macdonald JS, Kisner D, Smythe T, Woolley PV, Schein PS, Smith L: 5?Fluorouracil, methyl?CCNU and vincristine in the treatment of advanced colorectal cancer. Pilot study utilizing weekly 5?fluorouracil. Cancer Treat Rep 60:1597?1600, 1976.

Morgan LR, Schein PS, Woolley PV, Hoth D, Macdonald JS, Lippman M, Posey L, Beazley RS: Therapeutic use of tamoxifen in advanced breast cancer: A correlation with biochemical parameters. Cancer Treat Rep 60:1437?1443, 1976.

Macdonald JS, Wunderlich JR, Yankee RA, Yyst I: Lymphocyte dependent antibody: A new mechanism of immune lysis of human platelets. Clin Exp Immunol 31:259?265, 1975.

Schein PS, Macdonald JS, Waters C, Haidak D: Nutritional complications of cancer and its treatment. Semin Oncol 3:337?347, 1975.

Schein PS, Kisner D, Macdonald JS: Chemotherapy of large intestinal carcinoma: Current results and future prospects. Cancer 36:2418?2420, 1975.

Wunderlich JR, Martin WJ, Macdonald JS: Functional efficiency of antitumor cytotoxic lymphoid cells. Isr J Med Sci 9:317?323, 1973.

Martin WJ, Wunderlich JR, Macdonald JS: Suppressed development of cytotoxic lymphoid cells in tumor immunized mice. Isr J Med Sci 9:324?331, 1973.

Wunderlich JR, Martin WJ, Macdonald JS, Fletcher F: Functional capacity of cytotoxic lymphoid cells. Monogr Natl Cancer Inst 34:243?249, 1972.

Macdonald JS, Goldberg IH: An effect of pactamycin on the initiation of protein synthesis in reticulocytes. Biochem Biophys Res Commun 41:1,1970.